Markets & Finance

Holcim has agreed to divest its Philippines cement business, Holcim Philippines Inc., to a subsidiary of China's Huaxin Building Materials in a structured two-stage transaction totaling at least USD 807 million. The first stage transfers a 67.6% indirect stake for approximately USD 527 million, with a remaining 31.4% stake subject to call and put options exercisable no earlier than 2030, carrying a USD 280 million minimum floor. Closing is targeted for the first half of 2027, contingent on approvals from Chinese regulators, the Philippine Competition Commission, and Huaxin shareholders, among other conditions.

AI counter-drone firm Space-Eyes signed a definitive merger agreement with McKinley Acquisition Corp on July 31, 2026, carrying an implied equity valuation of $638 million under a no-redemption assumption and a separately stated enterprise value of $370 million. Reuters and The Independent report the company generates approximately $1 million in annual revenue, with current contracts typically yielding $300,000 to $400,000 per year. The $638 million figure depends on zero shareholder redemptions from McKinley's trust account; industry-wide SPAC redemption rates exceeded 95% in many late-2025 deals, and audited financials and full transaction terms had not yet appeared in SEC filings as of August 3, 2026.

Krystal Biotech releases its second-quarter 2026 financial results before U.S. market open on August 3, with a management call at 8:30 a.m. ET. The most recent public baseline is Q1 2026 VYJUVEK net product revenue of $116.4 million, up 32% year over year, on a 95% gross margin and $55.9 million in net income. Q2 revenue, June 30 cash balances, updated prescriber metrics, and any changes to full-year expense guidance of $175 million to $195 million are not yet publicly available.

EverQuote is set to release its second-quarter 2026 financials after U.S. markets close on August 3, 2026, with management having guided for revenue between $185 million and $195 million and adjusted EBITDA of $28 million to $30 million. The most recent available baseline is Q1 2026, when the company posted $190.9 million in revenue, $18.7 million in GAAP net income, and held $178.5 million in cash with no debt. A single customer accounted for 40% of Q1 revenue, and carrier spending can be reduced without notice, making the Q2 vertical revenue breakdown and any outlook revision among the key figures to watch when results are published.

Ethos Technologies is set to release its Q2 2026 financials after U.S. markets close on August 3, with company guidance projecting revenue of $114 million to $118 million and adjusted EBITDA of $20 million to $22 million for the quarter. Third-party analyst consensus sits above that range at approximately $120.22 million. The release will be the first opportunity to assess whether the revenue scale and stable 98% gross margin seen in Q1 2026 continued, and how contribution and adjusted EBITDA margins trended following their year-over-year compression in the prior quarter.

GeneDx is set to release second-quarter 2026 financials after market close on August 3, with management guiding for revenue of $110 million to $112 million and approximately 30,000 exome and genome tests. The report arrives after the company cut its full-year 2026 revenue outlook from $540–$555 million to $475–$490 million following Q1 results in May. Q1 2026 showed $102.3 million in total revenue, a 67% GAAP gross margin, and a GAAP net loss of $63.3 million, providing the baseline against which today's figures will be measured.

Inspire Medical Systems is set to release second-quarter 2026 financials after trading closes on August 3, 2026, with a conference call at 5:00 p.m. Eastern. The most recent available data show Q1 2026 revenue of $204.6 million, an 86.5% gross margin, and full-year 2026 revenue guidance of $825 million to $875 million. Heading into the release, the company flagged ongoing reimbursement and coding uncertainty around its Inspire V device, an active Department of Justice civil investigative demand, and a patent suit filed by competitor Nyxoah.

SpaceX will release second-quarter 2026 financial results after market close on August 4, its first quarterly disclosure as a public company following a June IPO at $135 per share. The most recent available figures, from Q1 2026, show total revenue of $4.694 billion across Space, Connectivity, and AI segments, with cash of $15.852 billion and capital expenditures of $10.107 billion for the quarter. Actual Q2 revenue, operating income, segment breakdowns, and the June 30 balance sheet remain unreleased ahead of the webcast.

Kimberly-Clark will release its second-quarter 2026 financial results on August 4 at 6:30 a.m. EDT, followed by an analyst webcast at 8:00 a.m. EDT. The most recent available data is Q1 2026, which showed net sales of $4,163 million, 2.5% organic sales growth, and a 36.8% reported gross margin, with input costs running as an unfavorable 4.6% headwind. Readers tracking the August 4 release should focus on organic sales decomposition, the NA and IPC segment results, and any changes to the full-year guidance the company reaffirmed in April.

AGNT Inc., formerly eXp World Holdings, will report its second-quarter 2026 financial results on August 4 via a virtual investor session at 5 p.m. Eastern. The company enters the disclosure having posted $1.006 billion in Q1 2026 consolidated revenue, a 5% year-over-year increase, alongside a GAAP net loss of $5.1 million and adjusted EBITDA of $4.1 million. The release will be the first under the renamed holding-company structure and is expected to include Q2 figures, the initial contribution from the May 2026 NextHome acquisition, and any updates to the full-year 2026 revenue guidance of $4.85 billion to $5.15 billion.